Compare PLRX & FEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLRX | FEAM |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.3M | 78.3M |
| IPO Year | 2020 | N/A |
| Metric | PLRX | FEAM |
|---|---|---|
| Price | $1.53 | $3.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 2 |
| Target Price | $3.79 | ★ $8.13 |
| AVG Volume (30 Days) | ★ 762.4K | 96.7K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $500.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $2.82 |
| 52 Week High | $15.80 | $24.84 |
| Indicator | PLRX | FEAM |
|---|---|---|
| Relative Strength Index (RSI) | 42.21 | 43.49 |
| Support Level | $1.48 | $3.75 |
| Resistance Level | $1.63 | $4.11 |
| Average True Range (ATR) | 0.10 | 0.41 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 10.45 | 33.47 |
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.